Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Education, Pharmacy | 7 | 2026 | 63 | 1.550 |
Why?
|
| Students, Pharmacy | 5 | 2024 | 76 | 1.180 |
Why?
|
| Oxazolidinones | 5 | 2014 | 32 | 0.750 |
Why?
|
| Acetamides | 5 | 2014 | 43 | 0.750 |
Why?
|
| Pseudomonas aeruginosa | 4 | 2006 | 177 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 8 | 2014 | 2596 | 0.550 |
Why?
|
| Microbial Sensitivity Tests | 13 | 2014 | 859 | 0.480 |
Why?
|
| Ceftazidime | 1 | 2015 | 46 | 0.440 |
Why?
|
| Faculty | 2 | 2013 | 99 | 0.430 |
Why?
|
| Status Epilepticus | 1 | 2015 | 159 | 0.400 |
Why?
|
| Vancomycin | 4 | 2014 | 226 | 0.370 |
Why?
|
| Educational Measurement | 4 | 2024 | 320 | 0.340 |
Why?
|
| Antifungal Agents | 2 | 2012 | 292 | 0.330 |
Why?
|
| Critical Care | 1 | 2016 | 686 | 0.330 |
Why?
|
| Candidiasis, Invasive | 1 | 2010 | 24 | 0.300 |
Why?
|
| Leadership | 2 | 2024 | 255 | 0.280 |
Why?
|
| Streptococcus pneumoniae | 2 | 2001 | 389 | 0.280 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2010 | 401 | 0.260 |
Why?
|
| Bone Marrow Transplantation | 1 | 2010 | 589 | 0.250 |
Why?
|
| Staphylococcus aureus | 4 | 2006 | 483 | 0.240 |
Why?
|
| Gentamicins | 1 | 2006 | 88 | 0.240 |
Why?
|
| Intensive Care Units | 1 | 2010 | 526 | 0.240 |
Why?
|
| Thienamycins | 1 | 2005 | 12 | 0.230 |
Why?
|
| Streptococcus pyogenes | 2 | 2003 | 81 | 0.230 |
Why?
|
| Competency-Based Education | 1 | 2026 | 84 | 0.230 |
Why?
|
| Critical Illness | 1 | 2010 | 630 | 0.220 |
Why?
|
| beta-Lactams | 1 | 2005 | 56 | 0.220 |
Why?
|
| Emotional Intelligence | 1 | 2024 | 15 | 0.220 |
Why?
|
| Anti-Infective Agents | 3 | 2003 | 266 | 0.210 |
Why?
|
| Mentoring | 1 | 2026 | 85 | 0.210 |
Why?
|
| Academic Performance | 1 | 2024 | 24 | 0.210 |
Why?
|
| Antibody Formation | 1 | 2025 | 227 | 0.210 |
Why?
|
| Streptococcal Infections | 2 | 2003 | 254 | 0.200 |
Why?
|
| Gram-Positive Bacteria | 2 | 2014 | 44 | 0.200 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2003 | 25 | 0.200 |
Why?
|
| Clindamycin | 1 | 2003 | 40 | 0.190 |
Why?
|
| Exotoxins | 1 | 2003 | 44 | 0.190 |
Why?
|
| Linezolid | 5 | 2014 | 25 | 0.190 |
Why?
|
| Faculty, Pharmacy | 2 | 2026 | 11 | 0.190 |
Why?
|
| Penicillins | 1 | 2003 | 154 | 0.180 |
Why?
|
| Ciprofloxacin | 2 | 2001 | 66 | 0.170 |
Why?
|
| Absenteeism | 1 | 2020 | 20 | 0.160 |
Why?
|
| Influenza Vaccines | 1 | 2025 | 507 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 1173 | 0.150 |
Why?
|
| Models, Psychological | 1 | 2020 | 138 | 0.150 |
Why?
|
| Curriculum | 3 | 2024 | 798 | 0.140 |
Why?
|
| Teaching | 1 | 2020 | 196 | 0.140 |
Why?
|
| Models, Biological | 4 | 2006 | 1371 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2025 | 1176 | 0.140 |
Why?
|
| Staphylococcal Infections | 1 | 2003 | 571 | 0.140 |
Why?
|
| Gram-Positive Bacterial Infections | 3 | 2014 | 71 | 0.130 |
Why?
|
| Bacterial Proteins | 1 | 2003 | 953 | 0.130 |
Why?
|
| Humans | 25 | 2026 | 131163 | 0.130 |
Why?
|
| Online Systems | 1 | 2016 | 16 | 0.120 |
Why?
|
| Gene-Environment Interaction | 1 | 2017 | 127 | 0.120 |
Why?
|
| Problem-Based Learning | 1 | 2016 | 81 | 0.120 |
Why?
|
| Colony Count, Microbial | 3 | 2006 | 86 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 1 | 2015 | 57 | 0.110 |
Why?
|
| Myoclonus | 1 | 2015 | 31 | 0.110 |
Why?
|
| Membrane Proteins | 1 | 2003 | 1590 | 0.110 |
Why?
|
| Schools, Pharmacy | 3 | 2026 | 27 | 0.110 |
Why?
|
| Young Adult | 5 | 2024 | 10103 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 707 | 0.100 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 531 | 0.100 |
Why?
|
| Aminoglycosides | 1 | 2014 | 45 | 0.100 |
Why?
|
| Drug Resistance, Fungal | 2 | 2012 | 31 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2020 | 919 | 0.100 |
Why?
|
| Internet | 1 | 2016 | 420 | 0.100 |
Why?
|
| Daptomycin | 1 | 2013 | 17 | 0.100 |
Why?
|
| Bacteremia | 2 | 2015 | 446 | 0.090 |
Why?
|
| Fungi | 1 | 2012 | 74 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 2 | 2025 | 393 | 0.090 |
Why?
|
| Escherichia coli | 2 | 2010 | 991 | 0.090 |
Why?
|
| Fluoroquinolones | 2 | 2003 | 96 | 0.090 |
Why?
|
| Data Collection | 1 | 2013 | 370 | 0.080 |
Why?
|
| Societies, Pharmaceutical | 2 | 2026 | 15 | 0.080 |
Why?
|
| Adult | 6 | 2025 | 31282 | 0.080 |
Why?
|
| Quinolones | 1 | 2010 | 60 | 0.080 |
Why?
|
| Male | 8 | 2025 | 64957 | 0.080 |
Why?
|
| Platelet Transfusion | 1 | 2010 | 55 | 0.080 |
Why?
|
| Leukopenia | 1 | 2010 | 44 | 0.080 |
Why?
|
| Professional Practice | 1 | 2010 | 39 | 0.080 |
Why?
|
| Platelet Count | 1 | 2010 | 139 | 0.080 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2010 | 46 | 0.080 |
Why?
|
| Sex Factors | 1 | 2013 | 1356 | 0.070 |
Why?
|
| Pharmacists | 1 | 2010 | 104 | 0.070 |
Why?
|
| Peer Review | 1 | 2008 | 34 | 0.070 |
Why?
|
| Publications | 1 | 2008 | 36 | 0.070 |
Why?
|
| Neutropenia | 1 | 2010 | 209 | 0.070 |
Why?
|
| Neoplasms | 2 | 2014 | 3016 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 223 | 0.070 |
Why?
|
| Escherichia coli Infections | 1 | 2010 | 198 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 670 | 0.070 |
Why?
|
| In Vitro Techniques | 2 | 2006 | 808 | 0.060 |
Why?
|
| Communicable Diseases | 1 | 2008 | 155 | 0.060 |
Why?
|
| Age Factors | 1 | 2013 | 2825 | 0.060 |
Why?
|
| Gram-Positive Cocci | 1 | 2005 | 2 | 0.060 |
Why?
|
| Porins | 1 | 2005 | 37 | 0.060 |
Why?
|
| Female | 7 | 2025 | 70963 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 254 | 0.060 |
Why?
|
| beta-Lactam Resistance | 1 | 2005 | 48 | 0.050 |
Why?
|
| Megakaryocytes | 1 | 2025 | 40 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2025 | 55 | 0.050 |
Why?
|
| Blood Platelets | 2 | 2025 | 313 | 0.050 |
Why?
|
| Kinetics | 1 | 2006 | 1088 | 0.050 |
Why?
|
| Middle Aged | 3 | 2015 | 28601 | 0.050 |
Why?
|
| Social Responsibility | 1 | 2024 | 86 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 2904 | 0.050 |
Why?
|
| Pseudomonas Infections | 1 | 2005 | 118 | 0.050 |
Why?
|
| Biofilms | 1 | 2005 | 96 | 0.050 |
Why?
|
| Proteus mirabilis | 1 | 2003 | 14 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2006 | 483 | 0.050 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 143 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1618 | 0.050 |
Why?
|
| Virulence | 1 | 2003 | 268 | 0.050 |
Why?
|
| Cross Infection | 1 | 2005 | 339 | 0.040 |
Why?
|
| DNA Topoisomerase IV | 1 | 2001 | 10 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2001 | 24 | 0.040 |
Why?
|
| DNA Gyrase | 1 | 2001 | 26 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2001 | 24 | 0.040 |
Why?
|
| Half-Life | 1 | 2001 | 149 | 0.040 |
Why?
|
| Glycopeptides | 1 | 2001 | 24 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 2001 | 195 | 0.040 |
Why?
|
| Animal Testing Alternatives | 1 | 2000 | 3 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2001 | 304 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2024 | 17753 | 0.040 |
Why?
|
| Behavior Control | 1 | 2020 | 10 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2000 | 149 | 0.040 |
Why?
|
| Endocarditis, Bacterial | 1 | 2000 | 128 | 0.040 |
Why?
|
| Animals | 4 | 2012 | 33912 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 99 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2020 | 148 | 0.040 |
Why?
|
| Social Behavior | 1 | 2020 | 214 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2025 | 712 | 0.030 |
Why?
|
| Motivation | 1 | 2020 | 328 | 0.030 |
Why?
|
| United States | 3 | 2026 | 12072 | 0.030 |
Why?
|
| Time Factors | 1 | 2006 | 6196 | 0.030 |
Why?
|
| Aged | 2 | 2013 | 21025 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 327 | 0.020 |
Why?
|
| Mycoses | 1 | 2012 | 110 | 0.020 |
Why?
|
| Pharmacy Administration | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2010 | 32 | 0.020 |
Why?
|
| Pharmaceutical Services | 1 | 2010 | 34 | 0.020 |
Why?
|
| Professional Role | 1 | 2010 | 78 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2010 | 149 | 0.020 |
Why?
|
| Periodicals as Topic | 1 | 2008 | 182 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 2701 | 0.010 |
Why?
|
| Enterococcus faecium | 1 | 2005 | 19 | 0.010 |
Why?
|
| Staphylococcus epidermidis | 1 | 2005 | 39 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 109 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2003 | 164 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2013 | 6797 | 0.010 |
Why?
|
| Naphthyridines | 1 | 2000 | 15 | 0.010 |
Why?
|
| Enterococcus | 1 | 2000 | 30 | 0.010 |
Why?
|
| Rabbits | 1 | 2000 | 575 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 501 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2013 | 15110 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 20987 | 0.010 |
Why?
|
| Child | 1 | 2013 | 26341 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2000 | 4697 | 0.000 |
Why?
|